

Global Benign Prostatic Hyperplasia (BPH) Medication Market Growth 2023-2029

<https://marketpublishers.com/r/G7387450661FEN.html>

Date: February 2023

Pages: 127

Price: US\$ 3,660.00 (Single User License)

ID: G7387450661FEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man's life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

LPI (LP Information)' newest research report, the "Benign Prostatic Hyperplasia (BPH) Medication Industry Forecast" looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Medication sales in 2022, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Medication sales for 2023 through 2029. With Benign Prostatic Hyperplasia (BPH) Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Benign Prostatic Hyperplasia (BPH) Medication industry.

This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Medication market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Medication and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Medication.

The global Benign Prostatic Hyperplasia (BPH) Medication market size is projected to grow from US\$ 3257.1 million in 2022 to US\$ 4151.5 million in 2029; it is expected to grow at a CAGR of 4151.5 from 2023 to 2029.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Medication market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

5-Alpha-Reductase Inhibitors

Beta-Blockers

Botanicals and Traditional Chinese Medicine

Segmentation by application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Bayer HealthCare

Bristol-Myers Squibb

Valeant Pharmaceuticals

Endo Pharmaceuticals

Foresee Pharmaceuticals

Merck

Novartis

Advaxis

Teva Pharmaceutical Industries

Urologixs

Agennix

ANI Pharmaceuticals

BHR Pharma

Boehringer Ingelheim

Sanpower Group

Eisai

Ferring

IO THERAPEUTICS

LIDDS

Madrigal Pharmaceuticals

Nymox Pharmaceutical

Spectrum Pharmaceuticals

Takeda Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Benign Prostatic Hyperplasia (BPH)

Medication market?

What factors are driving Benign Prostatic Hyperplasia (BPH) Medication market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Benign Prostatic Hyperplasia (BPH) Medication market opportunities vary by end market size?

How does Benign Prostatic Hyperplasia (BPH) Medication break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales 2018-2029

- 2.1.2 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH)

Medication by Geographic Region, 2018, 2022 & 2029

- 2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH)

Medication by Country/Region, 2018, 2022 & 2029

2.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type

- 2.2.1 5-Alpha-Reductase Inhibitors

- 2.2.2 Beta-Blockers

- 2.2.3 Botanicals and Traditional Chinese Medicine

2.3 Benign Prostatic Hyperplasia (BPH) Medication Sales by Type

- 2.3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)

- 2.3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Type (2018-2023)

- 2.3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Type (2018-2023)

2.4 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application

- 2.4.1 Hospital Pharmacies

- 2.4.2 Retail Pharmacies

- 2.4.3 Online Pharmacies

2.5 Benign Prostatic Hyperplasia (BPH) Medication Sales by Application

- 2.5.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Market Share by Application (2018-2023)

2.5.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue and Market Share by Application (2018-2023)

2.5.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Application (2018-2023)

3 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY COMPANY

3.1 Global Benign Prostatic Hyperplasia (BPH) Medication Breakdown Data by Company

3.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Company (2018-2023)

3.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2018-2023)

3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Company (2018-2023)

3.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2018-2023)

3.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2018-2023)

3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Company

3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Location Distribution

3.4.2 Players Benign Prostatic Hyperplasia (BPH) Medication Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY GEOGRAPHIC REGION

4.1 World Historic Benign Prostatic Hyperplasia (BPH) Medication Market Size by Geographic Region (2018-2023)

4.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country/Region (2018-2023)

4.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Sales by Country/Region (2018-2023)

4.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue by Country/Region (2018-2023)

4.3 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Growth

4.4 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Growth

4.5 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Growth

4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Growth

5 AMERICAS

5.1 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country

5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023)

5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023)

5.2 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Type

5.3 Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region

6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018-2023)

6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2018-2023)

6.2 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Type

6.3 APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Benign Prostatic Hyperplasia (BPH) Medication by Country

7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
(2018-2023)

7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country
(2018-2023)

7.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type

7.3 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication by Country

8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by
Country (2018-2023)

8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by
Country (2018-2023)

8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Type

8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by
Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Medication

10.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication

10.4 Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Medication

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors

11.3 Benign Prostatic Hyperplasia (BPH) Medication Customer

12 WORLD FORECAST REVIEW FOR BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION BY GEOGRAPHIC REGION

12.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Region

12.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Region (2024-2029)

12.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Type

12.7 Global Benign Prostatic Hyperplasia (BPH) Medication Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Astellas Pharma

13.1.1 Astellas Pharma Company Information

13.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Astellas Pharma Main Business Overview

13.1.5 Astellas Pharma Latest Developments

13.2 Eli Lilly

13.2.1 Eli Lilly Company Information

13.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Eli Lilly Main Business Overview

13.2.5 Eli Lilly Latest Developments

13.3 GlaxoSmithKline

13.3.1 GlaxoSmithKline Company Information

13.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 GlaxoSmithKline Main Business Overview

13.3.5 GlaxoSmithKline Latest Developments

13.4 Sanofi

13.4.1 Sanofi Company Information

13.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Sanofi Main Business Overview

13.4.5 Sanofi Latest Developments

13.5 ADC Therapeutics

13.5.1 ADC Therapeutics Company Information

13.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 ADC Therapeutics Main Business Overview

13.5.5 ADC Therapeutics Latest Developments

13.6 Bayer HealthCare

- 13.6.1 Bayer HealthCare Company Information
- 13.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
- 13.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.6.4 Bayer HealthCare Main Business Overview
- 13.6.5 Bayer HealthCare Latest Developments
- 13.7 Bristol-Myers Squibb
 - 13.7.1 Bristol-Myers Squibb Company Information
 - 13.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Bristol-Myers Squibb Main Business Overview
 - 13.7.5 Bristol-Myers Squibb Latest Developments
- 13.8 Valeant Pharmaceuticals
 - 13.8.1 Valeant Pharmaceuticals Company Information
 - 13.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 Valeant Pharmaceuticals Main Business Overview
 - 13.8.5 Valeant Pharmaceuticals Latest Developments
- 13.9 Endo Pharmaceuticals
 - 13.9.1 Endo Pharmaceuticals Company Information
 - 13.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.9.4 Endo Pharmaceuticals Main Business Overview
 - 13.9.5 Endo Pharmaceuticals Latest Developments
- 13.10 Foresee Pharmaceuticals
 - 13.10.1 Foresee Pharmaceuticals Company Information
 - 13.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.10.4 Foresee Pharmaceuticals Main Business Overview
 - 13.10.5 Foresee Pharmaceuticals Latest Developments

13.11 Merck

13.11.1 Merck Company Information

13.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 Merck Main Business Overview

13.11.5 Merck Latest Developments

13.12 Novartis

13.12.1 Novartis Company Information

13.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Novartis Main Business Overview

13.12.5 Novartis Latest Developments

13.13 Advaxis

13.13.1 Advaxis Company Information

13.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 Advaxis Main Business Overview

13.13.5 Advaxis Latest Developments

13.14 Teva Pharmaceutical Industries

13.14.1 Teva Pharmaceutical Industries Company Information

13.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.14.4 Teva Pharmaceutical Industries Main Business Overview

13.14.5 Teva Pharmaceutical Industries Latest Developments

13.15 Urologixs

13.15.1 Urologixs Company Information

13.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

13.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.15.4 Urologixs Main Business Overview

- 13.15.5 Urologixs Latest Developments
- 13.16 Agennix
 - 13.16.1 Agennix Company Information
 - 13.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.16.4 Agennix Main Business Overview
 - 13.16.5 Agennix Latest Developments
- 13.17 ANI Pharmaceuticals
 - 13.17.1 ANI Pharmaceuticals Company Information
 - 13.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.17.4 ANI Pharmaceuticals Main Business Overview
 - 13.17.5 ANI Pharmaceuticals Latest Developments
- 13.18 BHR Pharma
 - 13.18.1 BHR Pharma Company Information
 - 13.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.18.4 BHR Pharma Main Business Overview
 - 13.18.5 BHR Pharma Latest Developments
- 13.19 Boehringer Ingelheim
 - 13.19.1 Boehringer Ingelheim Company Information
 - 13.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.19.4 Boehringer Ingelheim Main Business Overview
 - 13.19.5 Boehringer Ingelheim Latest Developments
- 13.20 Sanpower Group
 - 13.20.1 Sanpower Group Company Information
 - 13.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.20.4 Sanpower Group Main Business Overview
- 13.20.5 Sanpower Group Latest Developments
- 13.21 Eisai
 - 13.21.1 Eisai Company Information
 - 13.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.21.4 Eisai Main Business Overview
 - 13.21.5 Eisai Latest Developments
- 13.22 Ferring
 - 13.22.1 Ferring Company Information
 - 13.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.22.4 Ferring Main Business Overview
 - 13.22.5 Ferring Latest Developments
- 13.23 IO THERAPEUTICS
 - 13.23.1 IO THERAPEUTICS Company Information
 - 13.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.23.4 IO THERAPEUTICS Main Business Overview
 - 13.23.5 IO THERAPEUTICS Latest Developments
- 13.24 LIDDS
 - 13.24.1 LIDDS Company Information
 - 13.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.24.4 LIDDS Main Business Overview
 - 13.24.5 LIDDS Latest Developments
- 13.25 Madrigal Pharmaceuticals
 - 13.25.1 Madrigal Pharmaceuticals Company Information
 - 13.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
 - 13.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication

Sales, Revenue, Price and Gross Margin (2018-2023)

13.25.4 Madrigal Pharmaceuticals Main Business Overview

13.25.5 Madrigal Pharmaceuticals Latest Developments

13.26 Nymox Pharmaceutical

13.26.1 Nymox Pharmaceutical Company Information

13.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication

Product Portfolios and Specifications

13.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.26.4 Nymox Pharmaceutical Main Business Overview

13.26.5 Nymox Pharmaceutical Latest Developments

13.27 Spectrum Pharmaceuticals

13.27.1 Spectrum Pharmaceuticals Company Information

13.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication

Product Portfolios and Specifications

13.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.27.4 Spectrum Pharmaceuticals Main Business Overview

13.27.5 Spectrum Pharmaceuticals Latest Developments

13.28 Takeda Pharmaceuticals

13.28.1 Takeda Pharmaceuticals Company Information

13.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication

Product Portfolios and Specifications

13.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales, Revenue, Price and Gross Margin (2018-2023)

13.28.4 Takeda Pharmaceuticals Main Business Overview

13.28.5 Takeda Pharmaceuticals Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Benign Prostatic Hyperplasia (BPH) Medication Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Benign Prostatic Hyperplasia (BPH) Medication Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of 5-Alpha-Reductase Inhibitors

Table 4. Major Players of Beta-Blockers

Table 5. Major Players of Botanicals and Traditional Chinese Medicine

Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)

Table 7. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)

Table 8. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Type (2018-2023) & (\$ million)

Table 9. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2018-2023)

Table 10. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Type (2018-2023) & (USD/KG)

Table 11. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)

Table 12. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)

Table 13. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Application (2018-2023)

Table 14. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application (2018-2023)

Table 15. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Application (2018-2023) & (USD/KG)

Table 16. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Company (2018-2023) & (KG)

Table 17. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company (2018-2023)

Table 18. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Company (2018-2023) (\$ Millions)

Table 19. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company (2018-2023)

Table 20. Global Benign Prostatic Hyperplasia (BPH) Medication Sale Price by Company (2018-2023) & (USD/KG)

Table 21. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Producing Area Distribution and Sales Area

Table 22. Players Benign Prostatic Hyperplasia (BPH) Medication Products Offered

Table 23. Benign Prostatic Hyperplasia (BPH) Medication Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Geographic Region (2018-2023) & (KG)

Table 27. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share Geographic Region (2018-2023)

Table 28. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 29. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Geographic Region (2018-2023)

Table 30. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Country/Region (2018-2023) & (KG)

Table 31. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country/Region (2018-2023)

Table 32. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country/Region (2018-2023) & (\$ millions)

Table 33. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country/Region (2018-2023)

Table 34. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)

Table 35. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)

Table 36. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)

Table 38. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)

Table 39. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)

Table 40. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018-2023) & (KG)

Table 41. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region (2018-2023)

Table 42. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2018-2023)

Table 44. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)

Table 45. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)

Table 46. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)

Table 47. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)

Table 48. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)

Table 50. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)

Table 51. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)

Table 52. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Country (2018-2023) & (KG)

Table 53. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Type (2018-2023) & (KG)

Table 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Application (2018-2023) & (KG)

Table 58. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Medication

Table 59. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Medication

Table 60. Key Industry Trends of Benign Prostatic Hyperplasia (BPH) Medication

Table 61. Benign Prostatic Hyperplasia (BPH) Medication Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Benign Prostatic Hyperplasia (BPH) Medication Distributors List
Table 64. Benign Prostatic Hyperplasia (BPH) Medication Customer List
Table 65. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Region (2024-2029) & (KG)
Table 66. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 67. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 68. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 69. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Region (2024-2029) & (KG)
Table 70. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 71. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 72. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 73. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Country (2024-2029) & (KG)
Table 74. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 75. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Type (2024-2029) & (KG)
Table 76. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Type (2024-2029) & (\$ Millions)
Table 77. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Forecast by Application (2024-2029) & (KG)
Table 78. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Forecast by Application (2024-2029) & (\$ Millions)
Table 79. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 80. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 81. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 82. Astellas Pharma Main Business

Table 83. Astellas Pharma Latest Developments

Table 84. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 85. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 86. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 87. Eli Lilly Main Business

Table 88. Eli Lilly Latest Developments

Table 89. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 90. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 91. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 92. GlaxoSmithKline Main Business

Table 93. GlaxoSmithKline Latest Developments

Table 94. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 95. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 96. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 97. Sanofi Main Business

Table 98. Sanofi Latest Developments

Table 99. ADC Therapeutics Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 100. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 101. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 102. ADC Therapeutics Main Business

Table 103. ADC Therapeutics Latest Developments

Table 104. Bayer HealthCare Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 105. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 106. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 107. Bayer HealthCare Main Business
Table 108. Bayer HealthCare Latest Developments
Table 109. Bristol-Myers Squibb Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 110. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 111. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 112. Bristol-Myers Squibb Main Business
Table 113. Bristol-Myers Squibb Latest Developments
Table 114. Valeant Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 115. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 116. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 117. Valeant Pharmaceuticals Main Business
Table 118. Valeant Pharmaceuticals Latest Developments
Table 119. Endo Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 120. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 121. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 122. Endo Pharmaceuticals Main Business
Table 123. Endo Pharmaceuticals Latest Developments
Table 124. Foresee Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 125. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 126. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 127. Foresee Pharmaceuticals Main Business
Table 128. Foresee Pharmaceuticals Latest Developments
Table 129. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 130. Merck Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 131. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue

(\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 132. Merck Main Business

Table 133. Merck Latest Developments

Table 134. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 135. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 136. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 137. Novartis Main Business

Table 138. Novartis Latest Developments

Table 139. Advaxis Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 140. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 141. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 142. Advaxis Main Business

Table 143. Advaxis Latest Developments

Table 144. Teva Pharmaceutical Industries Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 145. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 146. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 147. Teva Pharmaceutical Industries Main Business

Table 148. Teva Pharmaceutical Industries Latest Developments

Table 149. Urologixs Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 150. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 151. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 152. Urologixs Main Business

Table 153. Urologixs Latest Developments

Table 154. Agennix Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 155. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios

and Specifications

Table 156. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 157. Agennix Main Business

Table 158. Agennix Latest Developments

Table 159. ANI Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 160. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 161. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 162. ANI Pharmaceuticals Main Business

Table 163. ANI Pharmaceuticals Latest Developments

Table 164. BHR Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 165. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 166. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 167. BHR Pharma Main Business

Table 168. BHR Pharma Latest Developments

Table 169. Boehringer Ingelheim Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 170. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 171. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 172. Boehringer Ingelheim Main Business

Table 173. Boehringer Ingelheim Latest Developments

Table 174. Sanpower Group Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 175. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 176. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 177. Sanpower Group Main Business

Table 178. Sanpower Group Latest Developments

Table 179. Eisai Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 180. Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 181. Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 182. Eisai Main Business
Table 183. Eisai Latest Developments
Table 184. Ferring Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 185. Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 186. Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 187. Ferring Main Business
Table 188. Ferring Latest Developments
Table 189. IO THERAPEUTICS Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 190. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 191. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 192. IO THERAPEUTICS Main Business
Table 193. IO THERAPEUTICS Latest Developments
Table 194. LIDDS Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 195. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 196. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 197. LIDDS Main Business
Table 198. LIDDS Latest Developments
Table 199. Madrigal Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors
Table 200. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications
Table 201. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)
Table 202. Madrigal Pharmaceuticals Main Business
Table 203. Madrigal Pharmaceuticals Latest Developments
Table 204. Nymox Pharmaceutical Basic Information, Benign Prostatic Hyperplasia

(BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 205. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 206. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 207. Nymox Pharmaceutical Main Business

Table 208. Nymox Pharmaceutical Latest Developments

Table 209. Spectrum Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 210. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 211. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 212. Spectrum Pharmaceuticals Main Business

Table 213. Spectrum Pharmaceuticals Latest Developments

Table 214. Takeda Pharmaceuticals Basic Information, Benign Prostatic Hyperplasia (BPH) Medication Manufacturing Base, Sales Area and Its Competitors

Table 215. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Portfolios and Specifications

Table 216. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (\$ Million), Price (USD/KG) and Gross Margin (2018-2023)

Table 217. Takeda Pharmaceuticals Main Business

Table 218. Takeda Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Medication
- Figure 2. Benign Prostatic Hyperplasia (BPH) Medication Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate 2018-2029 (KG)
- Figure 7. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Benign Prostatic Hyperplasia (BPH) Medication Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of 5-Alpha-Reductase Inhibitors
- Figure 10. Product Picture of Beta-Blockers
- Figure 11. Product Picture of Botanicals and Traditional Chinese Medicine
- Figure 12. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type in 2022
- Figure 13. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Type (2018-2023)
- Figure 14. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Hospital Pharmacies
- Figure 15. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Hospital Pharmacies (2018-2023) & (KG)
- Figure 16. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Retail Pharmacies
- Figure 17. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Retail Pharmacies (2018-2023) & (KG)
- Figure 18. Benign Prostatic Hyperplasia (BPH) Medication Consumed in Online Pharmacies
- Figure 19. Global Benign Prostatic Hyperplasia (BPH) Medication Market: Online Pharmacies (2018-2023) & (KG)
- Figure 20. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2022)
- Figure 21. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Application in 2022
- Figure 22. Benign Prostatic Hyperplasia (BPH) Medication Sales Market by Company in

2022 (KG)

Figure 23. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Company in 2022

Figure 24. Benign Prostatic Hyperplasia (BPH) Medication Revenue Market by Company in 2022 (\$ Million)

Figure 25. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Company in 2022

Figure 26. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Geographic Region (2018-2023)

Figure 27. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Geographic Region in 2022

Figure 28. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)

Figure 29. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 (\$ Millions)

Figure 30. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)

Figure 31. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 (\$ Millions)

Figure 32. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)

Figure 33. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 (\$ Millions)

Figure 34. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales 2018-2023 (KG)

Figure 35. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue 2018-2023 (\$ Millions)

Figure 36. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022

Figure 37. Americas Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022

Figure 38. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)

Figure 39. Americas Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)

Figure 40. United States Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Canada Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Mexico Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth

2018-2023 (\$ Millions)

Figure 43. Brazil Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth

2018-2023 (\$ Millions)

Figure 44. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region in 2022

Figure 45. APAC Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Regions in 2022

Figure 46. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)

Figure 47. APAC Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)

Figure 48. China Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 49. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 50. South Korea Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 52. India Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Australia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 54. China Taiwan Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022

Figure 56. Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022

Figure 57. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)

Figure 58. Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)

Figure 59. Germany Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 60. France Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 61. UK Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Italy Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Russia Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Country in 2022

Figure 65. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Country in 2022

Figure 66. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2018-2023)

Figure 67. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Application (2018-2023)

Figure 68. Egypt Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 69. South Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Israel Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Turkey Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 72. GCC Country Benign Prostatic Hyperplasia (BPH) Medication Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Medication in 2022

Figure 74. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Medication

Figure 75. Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Medication

Figure 76. Channels of Distribution

Figure 77. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Forecast by Region (2024-2029)

Figure 78. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share Forecast by Region (2024-2029)

Figure 79. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share Forecast by Type (2024-2029)

Figure 80. Global Benign Prostatic Hyperplasia (BPH) Medication

I would like to order

Product name: Global Benign Prostatic Hyperplasia (BPH) Medication Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G7387450661FEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7387450661FEN.html>